Santaris and miRagen link on microRNA-targeted CV medicines
This article was originally published in Scrip
Executive Summary
Denmark's Santaris Pharma has formed a strategic alliance with US biopharmaceutical company miRagen Therapeutics to develop microRNA-targeted medicines for the treatment of cardiovascular (CV) disease.